Scientists uncover how PML virus hides from immune system

NCT ID NCT04453917

Completed Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 22 people with PML, a rare brain infection caused by the JC virus in those with weakened immune systems. Researchers collected blood, urine, and spinal fluid samples over six months to measure immune checkpoint molecules and antiviral responses. The goal was to see if these molecules help the virus evade the immune system, which could lead to new treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could point toward new treatments for PML by using immune checkpoint blockers to restore antiviral immunity.
What could go wrong: This is a small, observational study with only 22 participants, so results may not apply to all PML patients. It is early-stage research, not a treatment trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

progressive multifocal leukoencephalopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Contacts and locations

Locations

CHU Bordeaux

Bordeaux, France
CHU Montpellier

Montpellier, France
CHU de TOULOUSE

Toulouse, 31000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.